CellCentric Initiates DOMMINO-1 Trial of Inobrodib with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Pivotal Phase 2 study underway in UK and US to evaluate novel combination therapy for heavily pretreated patients

Mar. 31, 2026 at 1:22pm

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray style image showing the intricate molecular structure of a multiple myeloma cell, conveying the complex biology and need for innovative treatments in this disease.A novel combination therapy aims to offer a new treatment option for multiple myeloma patients who have exhausted other therapies.Boston Today

CellCentric, a clinical-stage biotech company, has initiated the DOMMINO-1 pivotal Phase 2 trial evaluating its investigational oral p300/CBP inhibitor inobrodib in combination with pomalidomide and dexamethasone (InoPd) for the treatment of relapsed or refractory multiple myeloma. The first patient has been dosed at The Royal Marsden NHS Foundation Trust in London, with additional sites now open in the UK and US. The trial aims to enroll 100 adult patients who have previously received a bispecific antibody and are refractory to certain other therapies.

Why it matters

Multiple myeloma is a condition with serial therapeutic options, and new treatment modalities are urgently needed, especially for patients who have relapsed or become refractory to existing therapies like bispecific antibodies. Inobrodib represents a novel mechanism of action that has shown promising efficacy and tolerability in combination with standard-of-care pomalidomide and dexamethasone, potentially addressing a major unmet need for heavily pretreated RRMM patients.

The details

The DOMMINO-1 trial is designed to assess the safety and efficacy of the InoPd regimen, with participants receiving inobrodib at a 20 mg dose. The primary endpoint is overall response rate, with secondary endpoints including progression-free survival, overall survival and duration of response. Eligible participants must have previously received a bispecific antibody and be refractory to at least one proteasome inhibitor, one anti-CD38 monoclonal antibody and pomalidomide.

  • The first patient was dosed at The Royal Marsden NHS Foundation Trust in London on March 31, 2026.
  • Additional sites are now open in the UK and US.

The players

CellCentric

A clinical-stage biotechnology company developing inobrodib as a first-in-a-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Naseer Qayum M.D., Ph.D.

Chief Strategy Officer and Head of R&D at CellCentric.

Charlotte Pawlyn, M.D.

Honorary Consultant Hematologist at The Royal Marsden NHS Foundation Trust, Group Leader in Myeloma Biology and Therapeutics at The Institute of Cancer Research, London, and Principal Investigator for the DOMMINO-1 study.

Nisha Joseph, M.D.

Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine in Atlanta and DOMMINO-1 principal investigator at the first U.S. trial site.

Got photos? Submit your photos here. ›

What they’re saying

“Dosing the first patient in DOMMINO-1 marks an important milestone as we advance InoPd in registration-enabling studies. Inobrodib 20 mg with pom + dex has demonstrated encouraging clinical activity, including a 60% objective response rate, and a tolerability profile consistent with pom-dex alone. Patients who are refractory to pomalidomide and have progressed following bispecifics or other BCMA-directed therapies have very limited options. We believe InoPd may deliver a transformative all-oral treatment for RRMM patients and look forward to further evaluating its potential in this Phase 2 trial.”

— Naseer Qayum M.D., Ph.D., Chief Strategy Officer and Head of R&D at CellCentric

“Advances in multiple myeloma treatment, including bispecific antibodies, have improved patient outcomes. However, many people ultimately relapse or become refractory to these therapies, and new treatment options are urgently needed. Inobrodib represents a novel mechanism through inhibition of p300/CBP and has demonstrated the ability to be used in combination with established therapies. We look forward to further evaluating InoPd in this trial.”

— Charlotte Pawlyn, M.D., Honorary Consultant Hematologist at The Royal Marsden NHS Foundation Trust, Group Leader in Myeloma Biology and Therapeutics at The Institute of Cancer Research, London, and Principal Investigator for the DOMMINO-1 study

“InoPd appears to be a promising option in multiple myeloma treatment, not only for its tolerability and efficacy observed to date, but also for the practical benefits it may offer patients. More than 70% of patients are treated in the community setting, and an all-oral regimen may facilitate and expand access for those living with this disease, as well as their caregivers and healthcare providers.”

— Nisha Joseph, M.D., Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine in Atlanta and DOMMINO-1 principal investigator at the first U.S. trial site

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This new combination therapy with inobrodib represents a promising novel approach to treating heavily pretreated relapsed or refractory multiple myeloma patients, who currently have limited options. The DOMMINO-1 trial will provide important data on the safety and efficacy of this all-oral regimen, which could potentially expand access to care for myeloma patients in the community setting.